US EditionPacira BioSciences Announces $300M Share Buyback and '5x30' Growth Plan: Double-Digit Revenue Growth Targeted
Summary by stocktitan.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
— $300 million aggregate share repurchase authorization– — Reinforces confidence in 5×30 plan – — Continued focus on margin expansion and operational efficiency — BRISBANE, Calif., April 17, 2025 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, […]
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
